Commendable Service award,
Food and Drug Administration, 1981, Group award of merit, 1983, 1988, Group Commendable Service award, 1989, 1992—93, 1995, 1999, Commr.'s Special citation, 1993, American College of Legal Medicine Gold Medal (2003)[1]
Rheinstein was director of the Drug Advertising and Labeling Division,
Food and Drug Administration, Rockville, 1974-1982;[4][5] he was acting deputy director Office of Drugs, 1982–83, acting director Office of Drugs; 1983–84, director Office of Drug Standards, 1984–90,[6][7] director medicine staff Office Health Affairs, 1990-99.[8][9] While at FDA Rheinstein developed precedents for Food and Drug Administration regulation of prescription drug promotion, initiated FDA’s first patient medication information program; implemented the Drug Price Competition and Patent Term Restoration Act of 1984, and authored medication goals for Healthy People 2000 and 2010.[10][11][12][13][14][15]Judy Woodruff interviewed Rheinstein about generic drug safety on the
McNeil-Lehrer NewsHour, 11 Dec 1985.[16]Stone Phillips interviewed Rheinstein about drug labeling on
Dateline NBC, March 31, 1992.[17]
Later career
From 1999 – 2004, Rheinstein was senior vice president for medical and clinical affairs, Cell Works, Inc., Baltimore. Among other projects, Cell Works wanted to develop a blood test for anthrax, similar to a system for cancer cells it produced. "It's something that companies like ours can incorporate into our diagnostic technology," Rheinstein told the
Washington Times. Biodefense projects "create new technologies, the spin-offs of which can be commercialized into some pretty good things."[18] In 2000 Rheinstein became president of Severn Health Solutions in Severna Park, Maryland. In 2010 Rheinstein was named president of the Academy of Physicians in Clinical Research [19] and in 2011 was named chairman of the
American Board of Legal Medicine. Rheinstein was named chairman of the
United States Adopted Names Council in 2012. Rheinstein is a member of
Phi Kappa Phi,[20] and vice-president of the Intercultural Friends Foundation.[21] Rheinstein is publisher of
Discovery Medicine and chairman of MedData Foundation.[22] He is president-elect of the Academy of Medicine of Washington, DC.[23] Sarah Gonzalez interviewed Rheinstein for
Planet Money, This is Your Brain on Drug Ads, 8 Sept 2021.[24]
^WILL PEOPLE COUGH UP $50 FOR $5 DRUG? ORGANIDIN'S MAKERS REPLACED AN INGREDIENT WITH ONE THAT'S AVAILABLE OVER THE COUNTER. THEY KEPT THE PRICE. Philadelphia Inquirer. Oct 14, 1994 A2.
^Hospitals' Fatal Mistakes Repeated Elsewhere. Beaver County Times. Oct 24, 1993
^Lazar EJ, Banks D, Graham C, Adams D, Rheinstein PH, Gross M, Witt AM.Drug company sponsorship of education: the response to the FDA draft concept paper. JAMA. 1992 Jul 1;268(1):53-4
PMID1608109
^Peck CC, Rheinstein PH. FDA regulation of prescription drug advertising. JAMA. 1990 Nov 14;264(18):2424-5
PMID2232001
^Rheinstein PH. Regulatory status of pancreatic enzyme preparations. JAMA. 1990 May 9;263(18):2491-2
PMID2329638
^Faich GA, Morrison J, Dutra EV Jr, Hare DB, Rheinstein PH. Reassurance about generic drugs. N Engl J Med. 1987 Jun 4;316(23):1473-5
PMID3574426